Application of cycloastragenol derivatives to preparation of medicament with anti-hepatic-fibrosis effect

Abstract

The invention discloses a category of cycloastragenol derivatives or pharmaceutically acceptable salt thereof and application thereof to preparation of an anti-hepatic-fibrosis medicament. According to the invention, a microbial conversion technology is utilized to successfully carry out structural modification on cycloastragenol, a plurality of novel compounds are obtained, and in-vitro anti-hepatic-fibrosis cell tests prove that the compounds have good anti-hepatic-fibrosis activities, can be used as active ingredients of the anti-hepatic-fibrosis medicament, and have wide application.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of cycloastragenol derivatives in the preparation of drugs for treating liver diseases, and more specifically to the application of cycloastragenol derivatives in the preparation of drugs for preventing and treating liver fibrosis. Background technique [0002] Liver fibrosis refers to the pathological process of proliferation of fibrous connective tissue in the liver when liver cells undergo necrosis and inflammatory stimulation. After various pathogenic factors lead to liver injury, hepatic stellate cells are activated to become myofibroblast-like cells with a strong ability to generate extracellular matrix, and then the production of collagenase inhibitors increases, and the activity of collagenase also decreases, making the liver The imbalance between the production and degradation of extracellular matrix eventually leads to the excessive deposition of liver collagen a...

AI Technical Summary

Problems solved by technology

However, cycloastragenol belongs to tetracyclic triterpenoids, lacks active groups, and has few reaction sites. It is difficult to prepare derivatives that meet the requirements by conventional chemical reaction methods.

Images